Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jul;6(4):417-22.
doi: 10.1517/14740338.6.4.417.

Safety and Adverse Effects Associated With GLP-1 Analogues

Affiliations
Review

Safety and Adverse Effects Associated With GLP-1 Analogues

Jeffrey W Stephens et al. Expert Opin Drug Saf. .

Abstract

The incretin mimetics are an emerging class of agents for the treatment of diabetes. So far, exenatide is licensed for use in the US and also became available in the UK in May 2007. Within development and Phase III trials, liraglutide may also be made available within the next 2 years. These agents enhance glucose-dependent insulin secretion and exhibit other antihyperglycaemic actions, which are of particular benefit to overweight patients with Type 2 diabetes. This article reviews the profile of adverse effects for these agents in relation to their current (exenatide) and anticipated (liraglutide) role in the management of Type 2 diabetes.

Similar articles

See all similar articles

Cited by 4 articles

MeSH terms

LinkOut - more resources

Feedback